SEC Form 4 · accession 0001209191-17-037516
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Graeme Bell
Officer — EVP, Chief Financial Officer
Period of report
Jun 2, 2017
Accepted (ET)
Jun 5, 2017 · 7:59 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 2, 2017 | A | 8,400 | $12.3736 | A | 8,400 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.25 to $12.49, inclusive.